Search Within

Jaclyn Frances Hechtman

  1. "GSK Faculty"
Formats
  1. Journal Article (74)
  2. Meeting Abstract (68)
  3. Review (2)
  4. Book Section (1)
  5. Guidelines (1)
  6. Research Letter (1)
Groups
  1. GSK Faculty (147)
  2. Human Oncology and Pathogenesis Program (133)
  3. Department of Pathology and Laboratory Medicine (132)
  4. Department of Medicine (126)
  5. Solid Tumor Oncology Division (126)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (95)

More Groups

People
  1. Marc Ladanyi (69)
  2. Michael Berger (66)
  3. Ahmet Zehir (52)
  4. David Solit (52)
  5. Jinru Shia (48)
  6. Nikolaus Schultz (47)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (3)
  4. 2022 (3)
  5. 2021 (10)
  6. 2020 (18)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Modern Pathology (17)
  3. Clinical Cancer Research (14)
  4. Laboratory Investigation (11)
  5. Journal of Molecular Diagnostics (10)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (36)
  2. American Association for Cancer Research (30)
  3. Nature Publishing Group (17)
  4. Nature Research (17)
  5. Elsevier Science, Inc. (11)
  6. Oxford University Press (9)

More Publishers

Results (147)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Colorectal carcinoma with double somatic mismatch repair gene inactivation: Clinical and pathological characteristics and response to immune checkpoint blockade
    Journal Article

    Wang, T.; Lee, L. H.; Vyas, M.; Zhang, L.; Ganesh, K.; Firat, C.; Segal, N. H.; Desai, A.; Hechtman, J. F.; Ntiamoah, P.; more...
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
    Journal Article

    Greally, M.; Chou, J. F.; Chatila, W. K.; Margolis, M.; Capanu, M.; Hechtman, J. F.; Tuvy, Y.; Kundra, R.; Daian, F.; Ladanyi, M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
    Guidelines

    Marchiò, C.; Scaltriti, M.; Ladanyi, M.; Iafrate, A. J.; Bibeau, F.; Dietel, M.; Hechtman, J. F.; Troiani, T.; López-Rios, F.; Douillard, J. Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • NTRK fusion detection across three assays and 29,000 tumors
    Meeting Abstract

    Solomon, J.; Sireci, N.; Drilon, A.; Mullaney, K.; Benayed, R.; Ladanyi, M.; Hechtman, J.
    Modern Pathology (2019)

    Fulltext@MSK | Save
  • V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer
    Journal Article

    Gao, Y.; Maria, A.; Na, N.; da Cruz Paula, A.; Gorelick, A. N.; Hechtman, J. F.; Carson, J.; Lefkowitz, R. A.; Weigelt, B.; Taylor, B. S.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • NTRK fusion detection across three assays and 29,000 tumors
    Meeting Abstract

    Solomon, J.; Sireci, N.; Drilon, A.; Mullaney, K.; Benayed, R.; Ladanyi, M.; Hechtman, J.
    Laboratory Investigation (2019)

    Fulltext@MSK | Save
  • Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer
    Journal Article

    Won, E.; Basunia, A.; Chatila, W. K.; Hechtman, J. F.; Chou, J. F.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
    Journal Article

    Mandal, R.; Samstein, R. M.; Lee, K. W.; Havel, J. J.; Wang, H.; Krishna, C.; Sabio, E. Y.; Makarov, V.; Kuo, F.; Blecua, P.; more...
    Science (2019)

    Fulltext@MSK | Save
  • Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high
    Journal Article

    Middha, S.; Yaeger, R.; Shia, J.; Stadler, Z. K.; King, S.; Guercio, S.; Paroder, V.; Bates, D. D. B.; Rana, S.; Diaz, L. A. Jr; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save